HL
Therapeutic Areas
Zenas BioPharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Obexelimab | IgG4-Related Disease (IgG4-RD) | Phase 3 |
| Orelabrutinib | Primary Immune Thrombocytopenia (ITP) | Phase 3 |
| ZB021 | Undisclosed Autoimmune Indication | Preclinical |
| ZB022 | Undisclosed Autoimmune Indication | Preclinical |
Leadership Team at Zenas BioPharma
LM
Lonnie Moulder
Chief Executive Officer and Chairman of the Board of Directors
JF
Joe Farmer
President and Chief Operating Officer
LV
Lisa von Moltke, M.D.
Head of Research and Development and Chief Medical Officer
JF
Jennifer Fox
Chief Business Officer and Chief Financial Officer
HL
Haley Laken, Ph.D.
Chief Scientific Officer
OO
Orlando Oliveira
Chief Commercial Officer
HS
Heinrich Schlieker, Ph.D.
Chief Technical Officer
JH
Jeff Held
Chief Legal Officer
CC
Caroline Chevalier
Chief Administrative Officer
PA
Patricia Allen
Board of Directors